The following apply to use of spironolactone in CHF
except:
A. It is indicated only in NYHA class III/IV cases
as additional drug to conventional therapy
B. It affords prognostic benefit in severe heart
failure over and above that afforded by ACE
inhibitors
C. It helps overcome refractoriness to diuretics
D. It affords rapid symptomatic relief
except:
A. It is indicated only in NYHA class III/IV cases
as additional drug to conventional therapy
B. It affords prognostic benefit in severe heart
failure over and above that afforded by ACE
inhibitors
C. It helps overcome refractoriness to diuretics
D. It affords rapid symptomatic relief